Tonix Pharmaceuticals Holding Corp. (TNXP) stock
TNXPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 10/3083% below fair value
$2.94+0.06 (+2.08%)
Close on Nov 17, 2026Market cap $50.42MP/E –Yield –
Tonix Pharmaceuticals price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Tonix Pharmaceuticals's price to sales ratio was 2.2× on Nov 11, 2026, against 15.8× a year earlier. Over the last 3 years it ranged from 0.1× to 27.2×, with a median of 8.1×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 2.2× | −13.2 |
| 2025 | Dec 31, 2025 | 15.4× | +10.9 |
| 2024 | Dec 31, 2024 | 4.5× | – |
See a number that looks wrong?